Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0050 • ACR Convergence 2022
Effect of Disease-modifying Anti-rheumatic Drugs on Lung Microenvironment of SKG Mice
Sung Hae Chang¹, Jeongjun Choe², Seon Uk Kim³, Jeong Yeon Kim⁴, Sung Won Lee⁵, Jeong Seok Lee⁶ and Eun Young Lee⁴, ¹Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, ²Sungkyunkwan University, Seoul, Republic of Korea, ³Seoul National University College of Medicine, Jongno-gu, Seoul, Republic of Korea, ⁴Seoul National University College of Medicine, Seoul, Republic of Korea, ⁵Sooncheonhyang University College of Medicine, Seoul, Republic of Korea, ⁶Korea Advanced Institute of Science and Technology, KAIST, Graduate school of Medical Science and Engineering, Daejeon, Republic of Korea
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the pivotal extrapulmonary conditions. However, the pathophysiology of RA-ILD, including the effect of disease-modifying anti-rheumatoid…
Abstract Number: 0095 • ACR Convergence 2022
Association of Urban vs. Rural Residence with New DMARD Initiation in US Veterans with Active Rheumatoid Arthritis
Luke Desilet¹, Harlan Sayles¹, Punyasha Roul², Jennifer Barton³, Gail Kerr⁴, Kaleb Michaud¹, Ted Mikuls⁵ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²UNMC, Omaha, NE, ³VA Portland Health Care System/OHSU, Portland, OR, ⁴Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁵Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: While a treat-to-target strategy is endorsed by the ACR RA Treatment Guidelines, many patient, social, and healthcare system factors make implementation of this approach…
Abstract Number: 0207 • ACR Convergence 2022
Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App
Valentin Hamy¹, Christopher Llop², Christopher W Yee², Luis Garcia-Gancedo³, Aoife Maxwell⁴, Wen-Hung Chen⁵, Ryan Tomlinson³, Priyanka Bobbili², Julien Bendelac², Jessica Landry², Maral DerSarkissian⁶, Mihran Yenikomshian², Elinor A Mody⁷, Mei Sheng Duh² and Rachel Williams³, ¹GlaxoSmithKline, London, United Kingdom, ²Analysis Group Inc, Boston, MA, ³GlaxoSmithKline, Philadephia, ⁴GlaxoSmithKline, Stevenage, United Kingdom, ⁵GlaxoSmithKline, Value Evidence and Outcomes, Philadephia, ⁶Analysis Group Inc, Los Angeles, CA, ⁷Reliant Medical Group, Worcester, MA
Background/Purpose: RA symptoms are typically only assessed intermittently in clinical practice and clinical trials. Digital technologies (wearables, smartphones) can facilitate continuous remote monitoring of patients'…
Abstract Number: 0254 • ACR Convergence 2022
Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial
Katherine Liao¹, Jon Giles², Pamela Rist¹, Robert Glynn¹, Leah Santacroce¹, Paul Ridker¹, Ahmed Tawakol³, Joan Bathon² and Daniel Solomon¹, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Massachusetts General Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) treatments are known to cause complex changes in lipids, in part by controlling disease activity. While there are robust data on…
Abstract Number: 0270 • ACR Convergence 2022
Lower mRNA-anti SARS-Cov2 Induced IgG Antibody Responses to S1, S2 and RBD May Result from a Delayed IgA and IgM Class Switch in Patients with Rheumatoid Arthritis
Kristin Schmiedeberg¹, Irene Abela², Nicolas Vuilleumier³, Johannes von Kempis⁴ and Andrea Rubbert-Roth⁵, ¹Cantonal Hospital St Gallen, St.Gallen, Switzerland, ²Institute of Medical Virology, University of Zurich, Zürich, Switzerland, ³Laboratory Medicine Division, University of Geneva, Geneva, Switzerland, ⁴Division of Rheumatology, Cantonal Hospital St.Gallen, St. Gallen, Switzerland, ⁵Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland
Background/Purpose: Anti-SARS-CoV2 mRNA vaccination may result in blunted humoral immune responses with lower peak titers and a different kinetic in patients with rheumatic diseases receiving…
Abstract Number: 0288 • ACR Convergence 2022
Comparison of the Effect of Different Janus Kinase Inhibitors on Activation, Function and Property of NK Cells to Control Cancer Cell Lines Proliferation: An Ex Vivo and in Vitro Study
Loïc Meudec¹, Pauline Richebé¹, Juliette Pascaud², Xavier Mariette³ and Gaetane Nocturne⁴, ¹Université Paris-Saclay, AP-HP-Hôpital Bicêtre, Le Kremlin Bicêtre, France, ²Université Paris-Saclay, INSERM U1184, Le Kremlin Bicêtre, France, ³Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ⁴APHP, Le Kremlin Bicêtre, France
Background/Purpose: Janus kinase inhibitors (JAKi) are effective treatments licensed in rheumatoid arthritis (RA). Concerns about a risk of cancer may arise with JAKi as in…
Abstract Number: 0305 • ACR Convergence 2022
Effect of Upadacitinib on Bone Erosion Repair in Rheumatoid Arthritis: A Pilot Study
Ho SO¹, Isaac Cheng¹, Vivian Hung² and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Blockade of JAK, preferably JAK1, by upadacitinib is a feasible approach to achieve erosion repair as it 1) is approved for the treatment of…
Abstract Number: 0510 • ACR Convergence 2022
MACE and VTE Across Upadacitinib Clinical Trial Programs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Christina Charles-Schoeman¹, Ernest Choy², Iain B McInnes³, Eduardo Mysler⁴, Peter Nash⁵, Kunihiro Yamaoka⁶, Ralph Lippe⁷, Nasser Khan⁸, Anna K Shmagel⁹, Hannah Palac⁹, Jessica Suboticki¹⁰ and Jeffrey Curtis¹¹, ¹Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, ²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Department of Rheumatology, OMI (Medical Research Organization), Buenos Aires, Argentina, ⁵School of Medicine, Griffith University, Sunshine Coast, Australia, ⁶Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ⁷AbbVie, Inc, Wiesbaden, Germany, ⁸AbbVie, Inc., Abbott Park, IL, ⁹AbbVie, Inc., North Chicago, IL, ¹⁰AbbVie, Inc., Mettawa, IL, ¹¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with untreated immune-mediated inflammatory diseases, such as RA, PsA, and AS, are at increased risk for major adverse cardiovascular events (MACE) and venous…
Abstract Number: 0579 • ACR Convergence 2022
Characterization of Terminal Uridyl Transferase Function in Response to Tumor Necrosis Factor-α in Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh, Farheen Sultan Shaikh and Salahuddin Ahmed, Washington State university, Spokane, WA
Background/Purpose: Terminal Uridyl Transferase (TUT) genes TUT4 and TUT7 mediate uridylation of mRNA and microRNAs to maintain cellular homeostasis via RNA turnover. Changes in the…
Abstract Number: 0602 • ACR Convergence 2022
Cellworks Biosimulation Model (CBM) for Rheumatoid Arthritis (RA), Accurately Captures Patient’s Disease Activity at the Molecular Level Using Their Omics Data and Can Bring Personalization to Treatment Selection in RA
Himanshu Grover¹, Ansu Kumar¹, Anushua Chakraborty¹, Susheel George Chandy¹, Vivek Patil¹, Swati Khandelwal¹, Vishwas Joseph¹, Deepak Anil Lala¹, Prashant Ramachandran Nair¹, Karthik Sundara Raju¹, Kunal Ghosh Roy¹, Shahabuddin Usmani¹, Aftab Alam¹, Swaminathan Rajagopalan¹, Yatin Mundkur¹ and Andrew Concoff², ¹Cellworks Group Inc., South San Francisco, CA, ²United Rheumatology, Hauppauge, NY
Background/Purpose: Patients with RA demonstrate varied individual responses to the many treatment options available. In the absence of accurate, precision prediction of medication response, current…
Abstract Number: 0620 • ACR Convergence 2022
Neovascularization Is Altered by Rheumatoid Arthritis Synovial Fibroblasts and Canstatin in Vitro and in Vivo
Corinna Heck¹, Daria Kürsammer¹, Klaus Frommer², Mona Arnold³, Stefan Rehart⁴, Ulf Müller-Ladner⁵ and Elena Neumann³, ¹Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Bad Nauheim, Germany, ²Justus Liebig University Gießen, Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany, ³JLU Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ⁴Agaplesion Markus Hospital, Dpt of Orthopaedics and Trauma Surgery, Frankfurt, Germany, ⁵JLU Campus KK, Bad Nauheim, Germany
Background/Purpose: In the pathogenesis of rheumatoid arthritis (RA), neovascularization is increased in the activated and inflamed synovium. RA synovial fibroblasts (RASF) are key players in…
Abstract Number: 0723 • ACR Convergence 2022
Risk of Major Adverse Cardiovascular and Venous Thromboembolism Events in Patients with Rheumatoid Arthritis Exposed to JAK Inhibitors versus Adalimumab: A Nationwide Cohort Study
Lea Hoisnard¹, Laura Pina Vegas², Rosemary Dray-Spira³, Alain Weill³, Mahmoud Zureik³ and Emilie sbidian⁴, ¹Fédération Hospitalo-Universitaire TRUE InnovaTive theRapy for immUne disordErs, Assistance Publique-Hôpitaux de Paris (AP-HP), Henri Mondor Hospital, Créteil, France, ²Service de Rhumatologie, AP-HP, Hôpital Henri Mondor, Créteil, France, ³EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France, ⁴Service de Dermatologie, AP-HP, Hôpital Henri Mondor, Créteil, France
Background/Purpose: To assess the risk of major adverse cardiovascular events (MACEs) and venous thromboembolism events (VTEs) among patients initiating a Janus kinase inhibitor (JAKi) (tofacitinib…
Abstract Number: 0787 • ACR Convergence 2022
Relationship Between Humoral and Cellular Immune Responses in Persons with Rheumatoid Arthritis Following a Third Dose of COVID-19 Vaccine
Sara Tedeschi¹, Daniel Solomon¹, Yuezhou Chen², Jack Ellrodt¹, Mary Grace Whelan¹, Jacklyn Stratton¹, Keigo Hayashi³, Noah Whiteman², Lin Chen¹, Ifeoluwakiisi Adejoorin¹, Kathryne Marks¹, Emma Gomez-Rivas¹, Deepak Rao¹, Anna Jonsson¹ and Duane Wesemann², ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Okayama, Japan
Background/Purpose: DMARDs that treat RA may reduce immune responses to COVID-19 vaccination. We compared measures of humoral and cell-mediated immunity in RA patients before and…
Abstract Number: 0892 • ACR Convergence 2022
Predicting Value of Circulating Semaphorin 4A for Rheumatoid Arthritis Progression and Response to Treatment
Jérôme Avouac¹, Eloïse Vandebeuque², Alice Combier³, lucile poiroux³, Alexia Steelandt³, Margaux Boisson³, Virginie Gonzalez⁴, Anne Cauvet⁴, Thomas Barnetche⁵, Marie Truchetet⁶, Christophe Richez⁷ and Yannick Allanore⁸, ¹University of Paris, Paris, France, ²hôpital Cochin, AP-HP AP-HP.Centre - Université Paris Cité, Paris, France, ³Hôpital Cochin, AP-HP.Centre - Université Paris Cité, Paris, France, ⁴INSERM U1016, Institut Cochin, Paris, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Bordeaux University Hospital, Bordeaux, France, ⁷Université de Bordeaux, Bordeaux, France, ⁸Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: The lack of validated tools to predict rheumatoid arthritis (RA) disease course warrants the development of new reliable biomarkers. We have previously detected increased…
Abstract Number: 0908 • ACR Convergence 2022
The Association of Cardiovascular Comorbidities with Remission in Rheumatoid Arthritis Patients Undergoing Treatment with Baricitinib and Conventional Synthetic DMARDs: A Post-Hoc Analysis
Arkady Manning-Bennett¹, Ashley Hopkins², Michael Sorich², Susanna Proudman³, David Foster¹, Ahmad Abuhelwa² and Michael Wiese¹, ¹University of South Australia, Adelaide, Australia, ²Flinders University, Adelaide, Australia, ³Rheumatology Unit, Royal Adelaide Hospital, and Discipline of Medicine, University of Adelaide, Adelaide, Australia
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that is characterised by inflammation in the synovium of diarthrodial joints and low-level inflammation in multiple…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].